Empagliflozin

Empagliflozin is an anti-diabetic drug, belongs to the class of blood glucose lowering drugs. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated as an adjunct to diet, exercise and standard care therapy, to reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes and established CV disease who have inadequate glycemic control. Empaglifozin is also indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

• Pure, stable, non-hygroscopic anhydrous, crystalline form
• Good control of impurity profile by handling 4 chemical steps in-house
• PSD tailored to FDF needs
• Technical support available on request

IUPAC name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Trade name: Jardiance
Other name: BI-10773

INHOUSE